Dr James B Durham, MD | |
4805 Ne Glisan St, Portland, OR 97213-2933 | |
(503) 215-4323 | |
(503) 215-0297 |
Full Name | Dr James B Durham |
---|---|
Gender | Male |
Speciality | Pathology |
Experience | 50 Years |
Location | 4805 Ne Glisan St, Portland, Oregon |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1578784369 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0105X | Pathology - Clinical Pathology/laboratory Medicine | MD24057 (Oregon) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Providence Portland Medical Center | Portland, OR | Hospital |
Providence St Vincent Medical Center | Portland, OR | Hospital |
Providence Milwaukie Hospital | Milwaukie, OR | Hospital |
Providence Newberg Medical Center | Newberg, OR | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Providence Health And Services Oregon | 3072415652 | 48 |
Providence Health And Services - Oregon | 5294901922 | 47 |
Providence Health And Services Oregon | 5395656284 | 102 |
Providence Health And Services Oregon | 6103728753 | 43 |
Providence Health And Services Oregon | 7315856010 | 61 |
Providence Health And Services Oregon | 9335057447 | 125 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Entity Name | Providence Health & Services Oregon |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1003991845 PECOS PAC ID: 5395656284 Enrollment ID: O20031113000626 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Entity Name | Providence Health & Services Oregon |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1114015971 PECOS PAC ID: 9335057447 Enrollment ID: O20031117000153 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Entity Name | Providence Health & Services Oregon |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1093976243 PECOS PAC ID: 3476450560 Enrollment ID: O20031217000186 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Entity Name | Providence Health & Services Oregon |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1578500492 PECOS PAC ID: 1557260106 Enrollment ID: O20040102000768 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Entity Name | Providence Health & Services Oregon |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1366536963 PECOS PAC ID: 6103728753 Enrollment ID: O20040123000371 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Entity Name | Providence Health & Services Oregon |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1952482275 PECOS PAC ID: 3072415652 Enrollment ID: O20040123000519 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Entity Name | Providence Health & Services Oregon |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1053862714 PECOS PAC ID: 7315856010 Enrollment ID: O20040304001330 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Entity Name | Providence Health & Services - Oregon |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1912282369 PECOS PAC ID: 5294901922 Enrollment ID: O20120319000430 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Dr James B Durham, MD Po Box 3395, Portland, OR 97208-3395 Ph: (503) 215-4323 | Dr James B Durham, MD 4805 Ne Glisan St, Portland, OR 97213-2933 Ph: (503) 215-4323 |
News Archive
BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
Researchers at the University of California, San Diego (UCSD) and the Moores UCSD Cancer Center have discovered what could be a novel drug target for an often difficult-to-treat form of leukemia.
University of Calgary Faculty of Kinesiology researcher Elias Tomaras says the idea came to him while watching track and field sprinters warm-up for a race. "If you watch sprinters, short distance speed skaters or cyclists before their race, they will often warm-up for one to two hours, including several brief bouts of high intensity exercise. From an exercise physiology point of view, it seemed like it might be pretty tiring."
Epithelial ovarian cancer (EOC) is the most lethal disease among gynecologic malignancies. Patients with an advanced disease often relapse due to the development of chemoresistance. Chemotherapy failure is a consequence of acquired drug resistance which may potentially be due to multiple mechanisms including miRNA-mediated gene regulation.
The connection between health insurance and mortality is really hard to pin down, even if insurance truly has strong protective effects. The uninsured in America are mainly non-elderly adults.
› Verified 3 days ago
Dr. Kevin P Sargeant, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-8276 Fax: 503-494-2025 | |
Mary Jo Drew, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 3131 N. Vancouver Ave., American Red Cross Pnw Regional Blood Services, Portland, OR 97227 Phone: 503-528-5920 | |
Dr. Judith Ann Ray, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1015 Nw 22nd Ave, Portland, OR 97210 Phone: 503-413-8259 Fax: 503-413-6267 | |
Matthew Carstens Frank, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 303-859-4275 | |
Sarah Walter, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1015 Nw 22nd Ave, Dept Of Pathology, Portland, OR 97210 Phone: 503-237-0507 | |
Matthew Evans, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1015 Nw 22nd Ave, Portland, OR 97210 Phone: 800-649-8730 | |
Jacob Tyler Abel, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-6096 |